Ras activation in human breast cancer

Breast Cancer Research and Treatment

Volumn 62, Issue 1, 2000, Pages 51-62

  von Lintig, F C ^a   Dreilinger, A D ^a   Varki, N M ^a   Wallace, A M ^a   Casteel, D E ^a   Boss, G R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Epidermal growth factor receptor; ErbB 2 receptor; Mitogen activated protein kinase; Ras

Indexed keywords

EPIDERMAL GROWTH FACTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN;

ARTICLE; BREAST CANCER; BREAST FIBROADENOMA; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE K RAS; ONCOGENE NEU; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR CELL LINE;

BREAST NEOPLASMS; FEMALE; FIBROADENOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; MAMMARY NEOPLASMS, ANIMAL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; POINT MUTATION; RAS PROTEINS; TUMOR CELLS, CULTURED;

EID: 0033861175     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006491619920     Document Type: Article

References (56)

1. Ras genes
2. Ras oncogenes in human cancer: A review
3. Molecular insights into breast cancer from transgenic mouse models
4. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
5. Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases
6. Aberrant function of the Ras signal transduction pathway in human breast cancer
7. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
8. Epidermal-growth-factor receptor status as predictor of early recurrence of death from breast cancer
9. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: Validation against ligand-binding assay and clinical relevance in breast cancer
10. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
11. Increased erbB-2 gene copies and expression in multiple stages of breast cancer
12. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors
13. CSF-1 and its receptor in ovarian, endometrial and breast cancer
14. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro
15. Hyperexpression of mitogen-activated protein kinase in human breast cancer
16. Ras target proteins in eukaryotic cells
17. Regulation of Ras proteins and their involvement in signal transduction pathways (Review)
18. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
19. Protein famesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice
20. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
21. Inhibition of famesyltransferase induces regression of mammary and salivary carcinomas in Ras transgenic mice
22. Reovirus therapy of tumors with activated Ras pathway
23. Determination of absolute amounts of GDP and GTP bound to Ras in mammalian cells: Comparison of parental and Ras-overproducing NIH 3T3 fibroblasts
24. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors
25. Proliferation of human malignant astrocytomas is dependent on Ras activation
26. Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated EGF receptor is mediated through the Ras-Shc-Grb2 pathway
27. Neutralizing monoclonal antibody against ras oncogene product p21 which impairs guanine nucleotide exchange
28. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway
29. Rapid detection of ras oncogenes in human tumors: Applications to colon, esophageal, and gastric cancer
30. Assay for nanogram quantities of DNA in cellular homogenates
31. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
32. Mutational activation of K-ras oncogene in human breast tumors
33. Frequency and spectrum of mutations at codons 12 and 13 of the K-ras gene in human tumors
34. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
35. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3
36. Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity
37. Epidermal growth factor and betacellulin mediate signal transduction through coexpressed ErbB2 and ErbB3 receptors
38. Primary rat embryo cells transformed by one or two oncogenes show different metastatic potentials
39. Biological and biochemical properties of human ras H genes mutated at codon 61
40. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
41. K-ras and p53 gene mutations in pancreatic cancer: Ductal and nonductal tumors progress through different genetic lesions
42. 2-M of ErbB2-positive breast cancer cells
43. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
44. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
45. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors
46. Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21(ras) in fibroblasts
47. The signaling pathway coupling epidermal growth factor receptors to activation ofp21(ras)
48. The epidermal growth factor receptor couples transforming growth factor-α, heparin-binding epidermal growth factor-like factor, and amphiregulin to neu, erbB-3, and erbB-4
49. Epidermal growth factor-related peptides activate distinct subsets of erbB receptors and differ in their biological activities
50. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells
51. Two erbB-4 transcripts are expressed in normal breast and in most breast cancers
52. Phase II study of weekly intravenous recombinant humanized anti-p185-HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer
53. Evidence that farnesyltransrase inhibitors suppress ras transformation by interfering with Rho activity
54. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating flinction of RhoB